Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer

Timmermans, Maite; Zwakman, N.; Sonke, Gabe S.; Vijver, Koen K. Van de; Duk, M. Jitze; Aa, M.A. van der; Kruitwagen, Roy F.P.M.

doi:10.1016/j.ejogrb.2019.07.010

Cited by 8 publications

(5 citation statements)

References 39 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, for patients who are not eligible for initial macroscopic complete resection and treated with neoadjuvant chemotherapy, the addition of hyperthermic intraperitoneal chemotherapy has demonstrated a 12-month increase in OS [ 10 ]. As biological prognostic factors, the perioperative kinetics of CA 125 has been found to influence the OS [ 11 ]. Moreover, patients with BRCA mutations have been shown to survive longer than others and harbor higher intrinsic platinum sensitivity [ 12 ], although, for other authors, BRCA mutations alone cannot explain the long-term survival [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

Fabbro

Colombo

Leaha

et al. 2020

Cancers

View full text Add to dashboard Cite

Objective: High-grade serous ovarian cancers (HGSOC) are heterogeneous, often diagnosed at an advanced stage, and associated with poor overall survival (OS, 39% at five years). There are few data about the prognostic factors of late relapses in HGSOC patients who survived ≥five years, long-term survivors (LTS). The aim of our study is to assess the probability of survival according to the already survived time from diagnosis. Methods: Data from HGSOC patients treated between 1995 and 2016 were retrospectively collected to estimate the conditional probability of survival (CPS), probability of surviving Y years after diagnosis when the patient had already survived X years, and to determine the LTS prognostic factors. The primary endpoint was OS. Results: 404 patients were included; 120 of them were LTS. Patients were aged 61 years (range: 20–89), WHO performance status 0–1 in 86.9% and 2 in 13.1%, and Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) staging III and IV in 82.7% and 17.3% patients. Breast cancer (BRCA) status was available in 116 patients (33% mutated), including 58 LTS (36% mutated). No macroscopic residual disease was observed in 58.4% patients. First-line platinum-based chemotherapy plus paclitaxel was administered in 80.4% of patients (median: six cycles (range: 1–14)). After a 9 point 3-year follow-up, median OS was four years (95% CI: 3.6–4.5). The CPS at five years after surviving one year was 42.8% (95% CI: 35.3–48.3); it increased to 81.7% (95% CI: 75.5–87.8) after four survived years. Progression-free interval>18 months was the only LTS prognostic factor in the multivariable analysis (hazard ratio (HR) = 0.23; 95% CI: 0.13–0.40; p < 0.001). Conclusion: The CPS provided relevant and encouraging clinical information on the life expectancy of HGSOC patients who already survived a period of time after diagnosis. LTS prognostic factors are useful for clinicians and patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

Fabbro

Colombo

Leaha

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition, we also analyzed the correlation between the decrease in postoperative CA125 and platinumsensitive/platinum-resistant relapse. In the past, perioperative CA125 levels was mainly used to evaluate the impact on PFS and OS, or to guide the timing of surgery for intermediate tumor cell reduction [26][27][28]. The correlation between perioperative CA125 decrease and platinumsensitive or platinum-resistant relapse was rarely described.…”

Section: Discussionmentioning

confidence: 99%

Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer

Wang¹,

Min²,

Li³

et al. 2022

Eur. J. Gynaecol. Oncol.

View full text Add to dashboard Cite

Objectives: To investigate the effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer. Methods: A retrospective study was performed among 210 patients with advanced ovarian cancer who were treated with neoadjuvant chemotherapy from May 1, 2007 to December 1, 2015. 121 patients with NACT-IDS (Neoadjuvant chemotherapy followed by interval debulking surgery) were enrolled. The patients were divided into observation group (NACT-IDS + IP group, n = 28) and control group (NACT-IDS + IV group, n = 93) depending on whether intraperitoneal chemotherapy was used after interval debulking surgery. The effects of intraperitoneal chemotherapy after NACT-IDS on PFS (progression-free survival) and OS (overall survival) were analyzed and the influencing factors were explored through multivariate analysis. The competitive model was used to analyze the effect of intraperitoneal chemotherapy after NACT-IDS on tumor recurrence. Toxicities associated with adjuvant chemotherapy were also analyzed between two groups. The effect of neoadjuvant chemotherapy cycles on prognosis and the correlation between postoperative CA125 decline and recurrence were evaluated. Results: Intraperitonal chemotherapy and R0 (no gross residual) were independent factors for PFS, with HRs of 0.560 (95% CI, 0.342-0.918, p = 0.022) and 0.578 (95% CI, 0.377-0.887, p = 0.012). There was no independent factor associated with OS. Significant difference in PFS was detected among the R0 + IP group, R0 + IV group, non-R0 + IP group and non-R0 + IV group. In patients with R0 tumor reduction, IP patients showed significantly better PFS, bonferronei adjusted p = 0.036. In patients without R0 tumor reduction, no significant difference was detected between IP and IV group, bonferronei adjusted p = 0.28. There were no significant differences of grade 3-4 toxicities, abdominal pain, treatment delays, dose reductions, and treatment modifications in NACT-IDS + IP group and NACT-IDS + IV group. Neoadjuvant chemotherapy cycles (≤3 and >3) were not the influencing factors of PFS or OS and did not affect platinum-sensitive relapse or platinumresistant relapse. The decrease in postoperative CA125 was not related to platinum-sensitive recurrence or platinum-resistant recurrence. Conclusions: Neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval debulking surgery could improve the PFS of patients with advanced epithelial ovarian cancer compared to intravenous chemotherapy without significant differences in toxicity.

show abstract

“…In this group, TP53 mutation and MUC16 mutation were the two most common types of gene mutation. MUC16 is a member of the mucin family glycoprotein, which has been used as a tumor marker in the early diagnosis of ovarian cancer and other tumors [ 28 , 29 ]. MUC16 can promote tumorigenesis in ovarian cancer and play a role in tumor proliferation [ 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations

et al. 2021

Aging

View full text Add to dashboard Cite

In this study, we explored the genomic and immune cell infiltration profiles among four distinct Hepatocellular carcinoma (HCC) types. This study included 100 patients (all tumors and adjacent liver tissues received WES sequencing) with HCC from the West China Hospital (WCH) and patients were divided into WCH-HBV-HCC group and WCH-NonHBV-HCC group. Additionally, this study included 106 HBV-related HCC (TCGA-HBV-HCC) and 69 alcoholic HCC (TCGA-Alcol-HCC) patients from the TCGA. We analyzed the high-frequency gene mutation, copy number variation (CNV), mutation spectrum, signatures and immune cell infiltration of these four groups. This study showed significant differences in gene mutation and CNV level among four HCC groups. Compared to genomic level, there is no significant difference between TCGA-HBV-HCC and TCGA-Alcol-HCC groups in fractions of tumor-infiltrating immune cells. According to the status of immune cell infiltration, patients were classified into immune-HIGH, immune-MIX and immune-LOW group, respectively. In the WCH-HBV-HCC and TCGA-HBV-HCC groups, more patients in the Immune-LOW group had TP53 mutation. Except for TP53, neither the other gene mutation nor tumor mutation burden was found to be associated with immune cell infiltration in the WCH-HBV-HCC, TCGA-HBV-HCC and TCGA-Alcol-HCC groups. In the CNV level, we found that samples with low immune infiltrate had higher number of deleted or amplified genes in the TCGA-HBV-HCC and TCGA-Alcol-HCC groups. We found comprehensive genomic heterogeneity among four HCC groups. The total gene CNV level, not the mutational burden of HCC, is associated with immune cell infiltration in HCC. TP53 mutation may injury the immune response of the HBV-related HCC.

show abstract

Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer

Cited by 8 publications

References 39 publications

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer

Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations

Contact Info

Product

Resources

About